Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
Bioxytran (OTCQB: BIXT) has signed a Non-Disclosure Agreement with the University of Georgia to evaluate its galectin antagonists as a potential treatment for bird flu in chickens. The research collaboration will be led by Dr. Daniel Perez, an expert in virology and poultry medicine who serves as CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine at the university.
The company's leading drug candidate, ProLectin-M, is a galectin antagonist designed to fight viral infections by targeting galectins - proteins involved in viral replication, inflammation, and fibrosis. The drug has shown promise in in vitro studies against viruses similar to the bird flu virus, suggesting potential applications in poultry treatment.
Bioxytran (OTCQB: BIXT) ha firmato un Accordo di Non Divulgazione con l'Università della Georgia per valutare i suoi antagonisti della galectina come potenziale trattamento per l'influenza aviaria nei polli. La collaborazione di ricerca sarà guidata dal Dr. Daniel Perez, esperto in virologia e medicina aviare, che ricopre il ruolo di Docente Affiliato CVI e Caswell Eidson Chair in Medicina Aviare presso l'università.
Il principale candidato terapeutico dell'azienda, ProLectin-M, è un antagonista della galectina progettato per combattere le infezioni virali mirando alle galectine - proteine coinvolte nella replicazione virale, infiammazione e fibrosi. Il farmaco ha mostrato promettenti risultati in studi in vitro contro virus simili a quello dell'influenza aviaria, suggerendo potenziali applicazioni nel trattamento avicolo.
Bioxytran (OTCQB: BIXT) ha firmado un Acuerdo de No Divulgación con la Universidad de Georgia para evaluar sus antagonistas de galectina como un tratamiento potencial para la gripe aviar en pollos. La colaboración de investigación será liderada por el Dr. Daniel Perez, un experto en virología y medicina aviar que se desempeña como Profesor Afiliado de CVI y Caswell Eidson Chair en Medicina Avícola en la universidad.
El principal candidato a fármaco de la empresa, ProLectin-M, es un antagonista de galectina diseñado para combatir infecciones virales al dirigirse a las galectinas - proteínas involucradas en la replicación viral, inflamación y fibrosis. El fármaco ha mostrado promesas en estudios in vitro contra virus similares al virus de la gripe aviar, sugiriendo aplicaciones potenciales en el tratamiento avícola.
Bioxytran (OTCQB: BIXT)는 조지아 대학교와 비밀유지 계약을 체결하여 닭의 조류 인플루엔자에 대한 잠재적 치료제로서의 갈렉틴 길항제를 평가합니다. 연구 협력은 Dr. Daniel Perez가 이끌며, 그는 바이러스학 및 가금류 의학의 전문가로서 대학에서 CVI 부교수 및 Caswell Eidson Chair in Poultry Medicine을 맡고 있습니다.
회사의 주요 약물 후보인 ProLectin-M은 바이러스 감염과 싸우기 위해 갈렉틴 - 바이러스 복제, 염증 및 섬유증에 관여하는 단백질을 표적으로 하는 갈렉틴 길항제입니다. 이 약물은 조류 인플루엔자 바이러스와 유사한 바이러스에 대한 시험관 내 연구에서 유망한 결과를 보여주었으며, 가금류 치료에 대한 잠재적 응용 가능성을 시사합니다.
Bioxytran (OTCQB: BIXT) a signé un Accord de Non-Divulgation avec l'Université de Géorgie pour évaluer ses antagonistes de galectine comme traitement potentiel de la grippe aviaire chez les poules. La collaboration de recherche sera dirigée par le Dr. Daniel Perez, un expert en virologie et médecine aviaire qui est membre du corps professoral affilié au CVI et titulaire de la chaire Caswell Eidson en médecine aviaire à l'université.
Le principal candidat médicament de l'entreprise, ProLectin-M, est un antagoniste de galectine conçu pour lutter contre les infections virales en ciblant les galectines - des protéines impliquées dans la réplication virale, l'inflammation et la fibrose. Le médicament a montré des résultats prometteurs dans des études in vitro contre des virus similaires à celui de la grippe aviaire, suggérant des applications potentielles dans le traitement avicole.
Bioxytran (OTCQB: BIXT) hat eine Geheimhaltungsvereinbarung mit der University of Georgia unterzeichnet, um seine Galektin-Antagonisten als potenzielle Behandlung für die Vogelgrippe bei Hühnern zu bewerten. Die Forschungskooperation wird von Dr. Daniel Perez geleitet, einem Experten für Virologie und Geflügelmedizin, der als CVI-affiliierter Dozent und Caswell Eidson Chair in Poultry Medicine an der Universität tätig ist.
Der führende Arzneimittelkandidat des Unternehmens, ProLectin-M, ist ein Galektin-Antagonist, der entwickelt wurde, um Virusinfektionen zu bekämpfen, indem er Galektine - Proteine, die an der viralen Replikation, Entzündung und Fibrose beteiligt sind - angreift. Das Medikament hat in vitro vielversprechende Ergebnisse gegen Viren gezeigt, die dem Vogelgrippevirus ähnlich sind, was auf potenzielle Anwendungen in der Geflügelbehandlung hindeutet.
- Established research collaboration with prestigious University of Georgia
- ProLectin-M shows promising in vitro results against similar viruses
- Early-stage research with no clinical proof of effectiveness yet
- No immediate revenue potential from the collaboration
In Vitro studies have shown promise against viruses similar to the bird flu virus
BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the signing of a Non-Disclosure Agreement (NDA) with the Board of Regents of the University System of Georgia by and on behalf of the University of Georgia. The collaboration will focus on evaluating Bioxytran’s galectin antagonist as a potential treatment for chickens infected with Bird Flu. The research will be led by Dr. Daniel Perez, a renowned expert in virology and poultry medicine, who holds multiple prestigious positions at the University of Georgia, including CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine.
Bioxytran’s leading drug candidate, ProLectin-M, is a novel galectin antagonist designed to combat viral infections by targeting galectins, which are proteins implicated in viral replication, inflammation, and fibrosis. In vitro studies have demonstrated its effectiveness against viruses similar to the Bird Flu virus, raising hopes for its potential application in poultry and beyond.
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in virology, degenerative diseases, and hypoxia. The company’s three core platform technologies—glycovirology, cancer metastasis, and oxygen delivery—underpin its innovative pipeline. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. For more information, visit www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What is the purpose of BIXT's collaboration with the University of Georgia?
How does BIXT's ProLectin-M work against viral infections?
What evidence supports BIXT's ProLectin-M potential effectiveness against bird flu?
Who is leading the BIXT bird flu research at the University of Georgia?
